Drug intelligence / Profile preview

TQ-B3395

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQ-B3395 is an oral small molecule inhibitor of phosphoinositide 3-kinase (PI3K), under development for the treatment of advanced cancers, including breast cancer, non-small-cell lung cancer, and small cell lung cancer. The drug is being developed by Zhengda Tianqing Pharmaceutical Group and Sailing Medical Technology, both associated with Sino Biopharmaceutical. Its mechanism of action involves inhibition of PI3K signaling pathways, which are implicated in tumor growth and survival. TQ-B3395 has been evaluated in phase 1 clinical trials for various oncology indications.

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on TQ-B3395.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-B3395.

Explore the full profile